Back to Search
Start Over
Altered Expression of α-Methylacyl-Coenzyme A Racemase in Prostatic Adenocarcinoma Following Hormone Therapy
- Source :
- American Journal of Clinical Pathology. 123:553-561
- Publication Year :
- 2005
- Publisher :
- Oxford University Press (OUP), 2005.
-
Abstract
- α-Methylacyl-coenzyme A racemase (AMACR) is a sensitive and specific tissue marker for the diagnosis of prostatic carcinoma. However, limited data are available on AMACR expression in residual prostatic carcinoma following hormone therapy. We analyzed 64 residual or recurrent prostatic adenocarcinomas following hormonal therapy for the expression of AMACR using a monoclonal antibody (P504S) to AMACR. In 20 localized cases, AMACR staining was absent in 11 (55%), 1+ in 6 (30%), and 2+ or 3+ in 3 (15%). However, in 15 metastatic cases, AMACR was absent in 1 (7%), 1+ in 3 (20%), and 2+ or 3+ in 11 (73%). None of the 29 postradiotherapy cases showed complete absence of AMACR staining: 2 (7%) were 1+, and 27 (93%) were 2+ or 3+. AMACR expression was reduced significantly in the majority of posthormonal residual carcinomas, whereas in postradiotherapy and in hormone-refractory metastatic prostatic adenocarcinoma, AMACR expression was retained. Therefore, the diagnosis of residual prostatic carcinoma after hormonal therapy using AMACR immunostaining must be interpreted with caution. Furthermore, AMACR might have a role in the recurrence of prostatic adenocarcinoma after medical therapy.
- Subjects :
- Pathology
medicine.medical_specialty
business.industry
medicine.medical_treatment
General Medicine
medicine.disease
medicine.anatomical_structure
Prostate
medicine
Cancer research
Carcinoma
Hormonal therapy
Immunohistochemistry
Adenocarcinoma
Hormone therapy
business
Metastatic Prostatic Adenocarcinoma
Immunostaining
Subjects
Details
- ISSN :
- 19437722 and 00029173
- Volume :
- 123
- Database :
- OpenAIRE
- Journal :
- American Journal of Clinical Pathology
- Accession number :
- edsair.doi...........e39fc99d52cc22cbfc84d04523f8e731